Novartis | NVS - Des Atouts

Prix De L'Action
144.74
Variation Quotidienne
0.49 0.34%
Mensuellement
-3.75%
Annuel
27.59%
Q2 Prévisions
142.62




Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Amgen USD 90.59B 445M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Bausch Health Companies USD 26.37B 458M 2025-12
Biogen USD 29.44B 232M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Canopy Growth CAD 1.11B 36.35M 2025-12
Corcept Therapeutics USD 836.65M 13.04M 2025-12
Drreddys Laboratories INR 6.26B 161.9M 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Glaxosmithkline GBP 82.34B 102.25M 2025-12
J&J USD 200.89B 1.68B 2026-03
Merck USD 129.55B 12.02B 2025-09
Novartis USD 110.95B 3.66B 2025-12
Novartis USD 110.95B 3.66B 2025-12
Pacira USD 1.26B 32.66M 2025-12
Perrigo USD 8.54B 1.55B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Phibro Animal Health USD 1.41B 20.03M 2025-12
Prestige Brands USD 3.49B 52.46M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 128.02B 1.22B 2026-03
Sanofi EUR 126.81B 25.48B 2025-12
Supernus Pharmaceuticals USD 1.45B 32.89M 2025-12
Zoetis USD 15.47B 308M 2025-12